Invites Biocore인바이츠바이오코아
216400 · KONEX · ₩216400 · 인바이츠바이오코아
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
With these assumptions the model gives no positive value.
- Enterprise value
- −₩1.3B
- Equity value
- −₩31B
- WACC
- 4.9%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Why the model and the price differ
The model gives no positive value at these assumptions. What we can see:
- To match today's price of ₩1,389, the model needs an operating margin of 14.2% every year (it uses 1.4%).
- In the projection, spending on equipment, software and working capital takes most or all of the after-tax operating profit, so free cash flow is thin. Companies that invest heavily often look like this until spending slows.
Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.
Bear / Base / Bull
- Bear
- —
- Base
- —
- Bull
- —
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (1.4%).
Revenue growth
- -10%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-23.1% a year, annual reports), fading to 3% by year 5.
- -6.7%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-23.1% a year, annual reports), fading to 3% by year 5.
- -3.5%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-23.1% a year, annual reports), fading to 3% by year 5.
- -0.2%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-23.1% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-23.1% a year, annual reports), fading to 3% by year 5.
Business
- 1.4%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 2 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 11.8%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 14.7%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 2 annual reports (cash flow statements; equipment and intangibles).
- -10%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 2 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.01%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-30.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 104 weeks of weekly returns against KOSPI (official index); raw beta 0.02, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.51%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (FY 2025)
- ₩17B
- Net debt (borrowings and leases − cash and deposits)
- ₩29B
- Shares
- 7,711,315
- Share price
- ₩1,389
- Market cap
- ₩11B
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|
| Revenue | ₩22B | ₩17B | ₩15B | ₩14B | ₩13B | ₩13B | ₩14B |
| Growth | — | −23.1% | −10.0% | −6.7% | −3.5% | −0.2% | 3.0% |
| EBIT | ₩326M | ₩218M | ₩210M | ₩196M | ₩189M | ₩188M | ₩194M |
| EBIT margin | 1.5% | 1.3% | 1.4% | 1.4% | 1.4% | 1.4% | 1.4% |
| After-tax EBIT | ₩237M | ₩158M | ₩152M | ₩142M | ₩137M | ₩137M | ₩141M |
| + Depreciation | — | — | ₩1.8B | ₩1.6B | ₩1.6B | ₩1.6B | ₩1.6B |
| − Capital spending | ₩1.8B | ₩3.6B | ₩2.2B | ₩2.1B | ₩2B | ₩2B | ₩2B |
| − Working capital | — | −₩28B | ₩166M | ₩100M | ₩49M | ₩2.7M | −₩40M |
| Free cash flow | — | — | −₩449M | −₩364M | −₩303M | −₩256M | −₩221M |
| Discount factor | — | — | 0.953 | 0.909 | 0.867 | 0.827 | 0.788 |
| Present value | — | — | −₩428M | −₩331M | −₩263M | −₩212M | −₩174M |
Terminal value ₩172M, worth ₩136M today: -11% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 3.9% | — | — | — | — | — |
| 4.4% | — | — | — | — | — |
| 4.9% | — | — | — | — | — |
| 5.4% | — | — | — | — | — |
| 5.9% | — | — | — | — | — |
Now (TTM)
- Market cap
- ₩11B
- Enterprise value
- ₩38B
- P/E
- —
- P/B
- 4.0×
- P/S
- 0.6×
- EV/EBITDA
- —
- Dividend yield
- 0.0%
Over time (at each year end)
| 2025 | 2024 | |
|---|---|---|
| Price | ₩4,555 | ₩5,410 |
| Market cap | ₩35B | ₩42B |
| P/E | — | — |
| P/B | 13.2× | 3.0× |
| P/S | 2.1× | 1.9× |
| EV/EBITDA | — | — |
| Dividend yield | 0.0% | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Invites Biocore | — | 4.0× | 0.6× | — | 0.0% |
| Samsung Biologics | 34.7× | 8.2× | 15.1× | — | 0.0% |
| Celltrion | 28.2× | 2.5× | 9.1× | — | 0.0% |
| Alteogen | 76.3× | 27.5× | 58.0× | — | 0.1% |
| SK biopharmaceuticals | 15.2× | 6.0× | 7.1× | — | 0.0% |
| Yuhan | 23.3× | 2.3× | 2.4× | 30.4× | 0.8% |
| HLB | — | 15.5× | 54.7× | — | 0.0% |
| Similar companies (median) | 28.2× | 7.1× | 12.1× | 30.4× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Invites Biocore / 인바이츠바이오코아 / 216400 / KRX:216400
Source: KRX statistical information